SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products...
Hence then, the article about carsgen submits dual ind applications for allogeneic bcma car t product ct0596 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 )
Also on site :
- 'Not Suitable for Work' Cast Reveal Their Dream Guest Stars (Exclusive)
- Fast-Food Workers Dread When You Order This—and It's Not What You Think
- Chainlink and Multinational Banking Consortia Launch Project Pangea To Develop T+0 Settlement Framework for International FX Markets